Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312–39. https://doi.org/10.1016/j.cell.2019.09.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17:157–72.

Article  PubMed  Google Scholar 

Chen X and Holtzman DM. Emerging role of innate and adaptive immunity in Alzheimer's disease. Immunity 2022;10.016

Sun N, Victor MB, Park YP, et al. Human microglial states dynamics in Alzheimer’s disease progression. Cell. 2023;186:4386–403.

Article  CAS  PubMed  Google Scholar 

Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–8.

Article  CAS  PubMed  Google Scholar 

Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669–73. https://doi.org/10.1038/s41586-019-1769-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schölwer I, Habib P, Voelz C, Rolfes L, Beyer C, Slowik A. NLRP3 depletion fails to mitigate inflammation but restores diminished phagocytosis in BV-2 cells after in vitro hypoxia. Mol Neurobiol. 2020;57:2588–99.

Article  PubMed  Google Scholar 

Lučiūnaitė A, McManus RM, Jankunec M, Rácz I, Dansokho C, Dalgėdienė I, et al. Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J Neurochem. 2020;155:650–61.

Article  PubMed  Google Scholar 

Friker LL, Scheiblich H, Hochheiser I V., Brinkschulte R, Riedel D, Latz E, et al. β-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. Cell Rep 2020;30:3743–3754.e6. https://doi.org/10.1016/j.celrep.2020.02.025

Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;jem.20171419.

Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci. 2018. https://doi.org/10.1073/pnas.1716095115.

Article  PubMed  PubMed Central  Google Scholar 

Jian M, Kwan JSC, Bunting M, Ng RCL, Chan KH. Adiponectin suppresses amyloid-β oligomer (AβO)-induced inflammatory response of microglia via AdipoR1-AMPK-NF-κB signaling pathway. J Neuroinflammation. 2019;16:1–19.

Article  CAS  Google Scholar 

Ng RCL, Chan KH. Potential neuroprotective effects of adiponectin in Alzheimer’s disease. Int J Mol Sci. 2017;18:1–13.

Article  Google Scholar 

Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J Biol Chem. 2003;278:50810–7.

Article  CAS  PubMed  Google Scholar 

Iwabu M, Okada-Iwabu M, Yamauchi T, Kadowaki T. Adiponectin/adiponectin receptor in disease and aging. Nat Publ Gr. 2015. https://doi.org/10.1038/npjamd.2015.13.

Article  Google Scholar 

Neumeier M, Weigert J, Buettner R, Wanninger J, Schäffler A, Mü AM, et al. Detection of adiponectin in cerebrospinal fluid in humans. Am J Physiol Endocrinol Metab. 2007;293:E965–9.

Article  CAS  PubMed  Google Scholar 

Kusminski CM, McTernan PG, Schraw T, Kos K, O’Hare JP, Ahima R, et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia. 2007;50:634–42.

Article  CAS  PubMed  Google Scholar 

Liu J, Guo M, Zhang D, Cheng S-Y, Liu M, Ding J, et al. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci. 2012;109:12248–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng RCL, Jian M, Ma OKF, Bunting M, Kwan JSC, Zhou GJ, et al. Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer’s disease mouse model. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0701-0.

Article  PubMed  PubMed Central  Google Scholar 

Park S, Kim DS, Kwon DY, Yang HJ. Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J Neuroendocrinol. 2011;23:687–98.

Article  CAS  PubMed  Google Scholar 

Waragai M, Adame A, Trinh I, Sekiyama K, Takamatsu Y, Une K, et al. Possible involvement of adiponectin, the anti-diabetes molecule, in the pathogenesis of Alzheimer’s disease. J Alzheimer’s Dis. 2016;52:1453–9.

Article  CAS  Google Scholar 

Ng RCL, Cheng OY, Kwan JSC, Ho PWL, Cheng KKY, Yeung PKK, et al. Chronic adiponectin deficiency leads to Alzheimer’s disease-like cognitive impairments through AMPK inactivation and cerebral insulin resistance in aged mice. Mol Neurodegener. 2016;11:1–16.

Article  Google Scholar 

Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, et al. TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease. J Exp Med. 2018;215:2247–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Transl Psychiatry. 2016;6.

Miao J, Shen LH, Tang YH, Wang YT, Tao MX, Jin KL, et al. Overexpression of adiponectin improves neurobehavioral outcomes after focal cerebral ischemia in aged mice. CNS Neurosci Ther. 2013;19:969–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A-stimulated microglial activation. J Neurosci. 2009;29:11982–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song M, Jin J, Lim J-E, Kou J, Pattanayak A, Rehman JA, et al. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer’s disease. J Neuroinflammation. 2011;8:92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang J, Wise L, Fukuchi KI. TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer’s disease. Front Immunol. 2020;11:1–16.

CAS  Google Scholar 

Cunningham SC, Dane AP, Spinoulas A, Logan GJ, Alexander IE. Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther. 2008;16:1081–8.

Article  CAS  PubMed  Google Scholar 

Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun. 2015;6:6176. https://doi.org/10.1038/ncomms7176.

Article  CAS  PubMed  Google Scholar 

Sharoar MG, Palko S, Ge Y, Saido TC, Yan R. Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains. Mol Neurodegener. 2021;16:1–17.

Article  Google Scholar 

Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer’s disease amyloid plaques. Proc Natl Acad Sci U S A. 2015;112:E3699–708.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hassiotis S, Manavis J, Blumbergs PC, Hattersley KJ, Carosi JM, Kamei M, et al. Lysosomal LAMP1 immunoreactivity exists in both diffuse and neuritic amyloid plaques in the human hippocampus. Eur J Neurosci. 2018;47:1043–53.

Article  PubMed  Google Scholar 

Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724–39. https://doi.org/10.1016/j.neuron.2016.05.003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aschauer DF, Kreuz S, Rumpel S. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS ONE. 2013;8:1–16.

Article  Google Scholar 

Rosenberg JB, Sondhi D, Rubin DG, Monette S, Chen A, Cram S, et al. Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase a cDNA to nonhuman primates. Hum Gene Ther Clin Dev. 2014;25:164–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24:59–67.

Article  CAS  PubMed  Google Scholar 

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704–12.

Article  CAS  PubMed  Google Scholar 

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377:2215–27.

Article  CAS